Validation of a new test for social-cognitive functioning
Official title: Social-cognitive Functioning: Validation of a New Neuropsychological Test and Prediction of Social Behavioural Disorders in Daily Life
Run by Assistance Publique - Hôpitaux de Paris · NCT05558709 · Data updated 2026-11-12
The REALSoCog game-like test will be tried to see if it detects social-cognitive problems in people with Alzheimer's disease, Lewy body dementia, or frontotemporal degeneration.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | February 4, 2026 |
| Main results expected | February 4, 2029 |
| Study ends | February 4, 2030 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT05558709 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–90 with a clinical diagnosis of Alzheimer's disease, Lewy body dementia, or frontotemporal degeneration who can consent, have MMSE ≥20, and do not have major sensory or psychiatric comorbidities.
✕Probably not a fit
People with severe cognitive impairment (MMSE <20), major sensory loss (e.g., blindness or profound deafness), or significant psychiatric/neurological comorbidities are unlikely to benefit from this test.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
REALSoCog is a novel serious-game neuropsychological task designed to reveal social-cognitive and social behavioral disturbances that may not be evident during routine clinic visits. In this study, patients with Alzheimer's disease, Lewy body dementia, or frontotemporal degeneration will complete REALSoCog alongside standard cognitive batteries (e.g., BCS) and caregiver-report questionnaires. Caregiver input and normative data will be used to compare performance and to calculate sensitivity and specificity for detecting social-cognitive deficits. The protocol targets adults aged 18–90 with MMSE ≥20 and excludes those with major sensory or psychiatric comorbidities to document socio-cognitive profiles across these diseases.
Why it matters
Potential benefit: If successful, REALSoCog could enable earlier and more accurate detection of social-cognitive problems, helping clinicians tailor care and support for patients and caregivers.
How similar studies have gone: Existing paper-and-pencil social-cognition tests and some game-based approaches have shown value, but REALSoCog is a novel, more ecological tool that still needs validation in these patient groups.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: For patients: * Patient aged between 18 and 90 years * Mini Mental State Examination (MMSE) score greater than or equal to 20 * Patient able to express his or her non-opposition to participate in the study in an informed and autonomous manner * Patient with a neurodegenerative pathology: FTD, AD or LBD. For caregivers: * Over 18 years of age * Regular contact with the patient (≥ 2 times per month) Exclusion Criteria: For patients: * Neurological or psychiatric comorbidity * Notable sensory disorders (e.g., profound or total deafness, age-related macular degeneration, blindness, etc.) that may interfere with experimental completion. * Opposition to participation in the study
Where it's running
-
Hôpital de la Pitié-Salpêtrière
Paris, France Recruiting
Study contacts
- Principal investigator: Marc VERNY, Pr — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Marc VERNY, Pr
- Email: marc.verny@aphp.fr
- Phone: 01 42 16 03 12
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarker Repository for Age-Related and Inherited Neurodegenerative Diseases
This study collects blood and genetic samples from people with neurodegenerative diseases and their families to build a shared resource for studying disease risk and biology.
-
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease in Real World Practice
This study will look at real-world safety and effectiveness of disease-modifying therapy (DMT) in adults with MCI or Alzheimer's dementia by comparing those who receive DMT in routine care to those who do not.
-
FAME: A Italian test to recognize famous faces and name them
This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.
-
Automated language analysis to help diagnose neurodegenerative diseases
A multilingual AI-powered language test is being tried to see if speech and language patterns can help differentiate Alzheimer’s, frontotemporal dementia, Lewy body dementia, and Parkinson’s from healthy aging.
-
LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment
A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.
-
Urolithin A for early Alzheimer’s disease: a test with a nutritional supplement
This trial tests whether taking urolithin A in addition to standard care helps people with early Alzheimer’s or mild cognitive impairment show better biomarkers and cognition.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.